Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): Final overall survival results from a randomized phase 3 trial

According to the final results of the randomized phase 3 SOPHIA trial, margetuximab plus chemotherapy did not demonstrate an overall survival (OS) benefit compared with trastuzumab plus chemotherapy in patients with previously treated HER2+ advanced breast cancer.